iiinova — where your digital self keeps evolving

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Jonathan Zager 🇺🇸 Moffit Cancer Center Presenting on Melanoma Staging and Molecular Testing Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement

062

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Øyvind Bruland 🇳🇴 Oslo Alpha-emitting Radionuclide-Therapy with Bio-degradable microparticles injected intra-peritoneally

052

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Markus Mille 🇩🇪 Discussing: Robotic Single Port SP Surgery Robotic single-port (SP) surgery, enabled by the da Vinci SP system, represents an advanced evolution in robotic-assisted surgery

082

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Anders Thornell 🇸🇪 Sahlgrenska Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated? Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.

042

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Laura Lorenzon 🇮🇹 Investigation and Management of GI Symptoms After Surgery This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field

032

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 2 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Stefan Stättner 🇦🇹 Discussing Robotic Liver Surgery Robotic liver surgery is moving from the acceptance to the standardization phase with emerging experience and higher availability of robotic systems.

042

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Wim Ceelen 🇧🇪 Ghent Physically Enhanced IP Drug Delivery Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.

042

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Elinor Bexe Lindskog 🇸🇪 The Immune Microenvironment in Peritoneal Metastases The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche

033

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/10/2025

Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Lasma Nikolaisone 🇱🇻 The Testimonial of a Young Rectal Cancer Patient Rectal cancer treatment saves lives — but what follows is often a silent struggle with side effects that few discuss openly #RectalCancer

032

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/09/2025

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin

264

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 03/10/2025

See you in Berlin for #ESMO25! The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 . We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.

071

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 03/10/2025

A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !! HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!

021

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 06/10/2025

NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo www.europeanpharmaceuticalreview.com/news/266702/... The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS

032

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 07/10/2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis www.sciencedirect.com/science/arti...

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 08/10/2025

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

041

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2025

A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury The Theranostic Revolution ✨ Early randomized results look promising 🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery #ProstateCancer

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 04/09/2025

A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹 ⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways ✅ Feasible in selected patients, with potential for long-term disease control ✅ Reduced toxicity burden vs continuous therapy 📊 Stronger evidence with ICI than TKI

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 05/09/2025

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.” 👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx

012

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 05/09/2025

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.” 📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.

021

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 05/09/2025

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Aug 28-Sept 4, 2025 REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/maThWN36_sc @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social

youtu.be

OncoAlert Weekly Round Up🚨 Aug 29-Sept 4 Covering ASTER70, CodeBreak300 IMmotion010 and more

YouTube video by OncoAlert 360

031

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/08/2025

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨 buff.ly/KVngjav Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/08/2025

You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/08/2025

Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma www.sciencedirect.com/science/arti... This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/08/2025

Join Our Collaborators at @SpringerIME to explore this new, FREE clinical pathway tool designed to help you detect and target NTRK fusions🧬 & HER2 mutations in #NSCLC 🫁 #LungCancer CLICK HERE👉https://buff.ly/FeMbJ0r

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/08/2025

Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

011

Reposted by Gil Morgan MD

Dr Joseph McCollom DO @realbowtiedoc.bsky.social · 18/07/2025

@weoncologists.bsky.social summarizes the @oncoalert.bsky.social round-up 🤠 #SuppOnc dataon #GA the pillar assessment for #olderadults #GIonc includes #agnostic treatments in #dMMR cancer 🧬 Be sure to not miss an update by signing up 🔗: oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

oncoalert360.com

THE ONCOALERT NETWORK

Welcome to OncoAlert

163

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/07/2025

The OncoAlert🚨Weekly Round Up Covering July 4-10, 2025 www.youtube.com/watch?v=ib45... 👉 REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtube.com

The TOP News THIS WEEK in Oncology July 4-10, 2025 : OncoAlert Weekly Round Up with Dr. Gil Morgan

YouTube video by OncoAlert 360

032

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 26/05/2025

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 @biagioricciutimd.bsky.social ‬ @stephenvliu.bsky.social @drsanjaypopat.bsky.social Ping @drjnaidoo.bsky.social

0178

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/05/2025

The #ASCO25 #OncoAlertTOP10 Abstracts in GI Oncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @realbowtiedoc.bsky.social‬ @arosen380.bsky.social‬ Ping ‪@gillsharlene.bsky.social‬

043

Reposted by Gil Morgan MD

Darcy Burbage, DNP, RN, AOCN @darcyburbage.bsky.social · 22/05/2025

Love the just in time education provided in the @oncoalert.bsky.social weekly roundup to keep me informed of the latest in cancer research! TY @weoncologists.bsky.social ! #oncologynursing

011

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2025

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer ascopubs.org/doi/full/10.... analyzed individual data from 48 randomized trials in metastatic #ColorectalCancer to understand how tumor characteristics evolve across treatment lines

031

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/05/2025

You're invited to join the Post-ASCO 2025 Breast Cancer Highlights webinar, hosted by VJOncology. Featuring expert presentations and in-depth discussions on key abstracts in #BreastCancer presented at ASCO 2025. Register Here 👉 us06web.zoom.us/webinar/regi... June 17, 2025 16:00–18:00 CEST

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 09/05/2025

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study out on Lancet Oncology by Blondeaux🇮🇹 & Lambertini 🇮🇹et al🌐 thelancet.com/journals/lan... youtu.be/z-BRKbIUco0

youtu.be

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer

out on Lancet Oncology by Blondeaux🇮🇹 & Lambertini 🇮🇹et al🌐https://thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00152-4/abstractIn a large int...

033

Reposted by Gil Morgan MD

Mirrors of Medicine @mirrorsofmedicine.bsky.social · 20/05/2025

Advancing breast cancer treatment in the era of molecular diagnostics thebreastonline.com/article/S096... Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]

thebreastonline.com

Advancing breast cancer treatment in the era of molecular diagnostics

Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations, marking a significant step forward in cancer care,...

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/05/2025

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee. www.jto.org/article/S155...

042

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/05/2025

Oncology Here & Now Pod/Web Cast🚨 Join Urology colleagues, Dr. @barbaramelao.bsky.social 🇧🇷and Dr. Philippe Spiess🇺🇸, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. youtu.be/pfkLTzWX4AU

youtu.be

Oncology Here & Now: GU Oncology With Dr. Melão & Dr. Spiess (Upper Tract Urothelial Carcinoma)

YouTube video by OncoAlert 360

063

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 14/05/2025

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC) www.jto.org/article/S155... The review also examines the incidence of actionable mutations, toxicity considerations, sequencing strategies, and ongoing trials

012

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/05/2025

Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started! 👉 www.medsir.org/events/asco2... MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/05/2025

NEWS FROM INDUSTRY: SOURCE MERCK KEYNOTE-B96 Update #OvarianCancer KEYNOTE-B96 (ENGOT-ov65) trial sees pembrolizumab combined with chemotherapy , w/ or w/o bevacizumab, improved PFS in patients w/ platinum-resistant recurrent #OvarianCancer regardless of PD-L1 www.merck.com/news/merck-a...

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2025

You are warmly invited to watch the Top Trials of the Year🚨 presented by some of the world’s leading experts. All sessions are free and available on demand NO REGISTRATION NEEDED, JUST CLICK AND WATCH ⭐ GU Oncology buff.ly/3hkYYG6 ⭐ #BreastCancer buff.ly/EH7RPPc

022

Reposted by Gil Morgan MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2025

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25 youtu.be/ydcXe_faQH0 A sub analysis was just published out on European Journal of Cancer:

youtu.be

VJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO ...

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.

032